Pharma major Lupin on Monday said that it has launched its Testosterone Topical Solution, 30 mg per actuation having received an approval from the United States Food and Drug Administration (FDA) earlier. “Lupin's Testosterone Topical Solution, 30 mg per actuation is the generic equivalent of Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation . It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone,” the company said in a filing to the Bombay Stock Exchange.
Testosterone Topical Solution, 30 mg per actuation had annual sales of approximately USD 179 million in the US (IQVIA MAT December 2017), the company said. Meanwhile, shares of company closed trade at Rs 821.30 apiece, up 1.75 per cent, on the Bombay Stock Exchange on Monday.